New Antibody Formats

1st Edition, Volume 369 - June 20, 2022
Editors: Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 4 0 2 - 6
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 4 1 0 - 1

New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting intere… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.

Cover image
Title Page
Table of Contents
Copyright
Contributors
Chapter One: Current innovative engineered antibodies
Abstract
1: Introduction
2: Historical overview of antibody engineering
3: Bispecific antibodies
4: Nanobodies
5: Intrabodies
6: Fine-tuning Fc-dependent effector functions
7: Antibody–drug conjugates
8: Engineered antibody fusion proteins
9: CAR-T and CAR-NK cells
10: Conclusions
Acknowledgments
References
Chapter Two: Opportunities and challenges of bi-specific antibodies
Abstract
1: Introduction
2: Cis- versus trans-targeting bispecific antibodies
3: Technical challenges in the design and production of bispecific antibodies
4: Examples of BsAbs approved for clinical application
5: Further opportunities for bispecific antibodies on the example of regulatory T-cells
6: Current bi-specific antibodies targeting regulatory T-cells
7: Concluding remarks
References
Chapter Three: Applications of trimerbodies in cancer immunotherapy
Abstract
1: Introduction
2: Next-generation antibodies
3: The trimerbody concept and evolution
4: Trimerbodies in cancer immunotherapy
5: Trimerbodies in cancer diagnosis
6: Conclusions and future prospects
References
Chapter Four: Anticalin®-based therapeutics: Expanding new frontiers in drug development
Abstract
1: Introduction
2: Anticalin protein technology
3: Format opportunities for Anticalin proteins
4: Plasma half-life engineering of Anticalin proteins
5: Anticalin protein based multispecifics for potential treatment of infectious diseases
6: Antibody-Anticalin fusion formats for cancer immunotherapy
7: Armoring cancer immunotherapies with Anticalin protein-based payloads
8: Inhalable Anticalin proteins for local lung delivery
9: Concluding remarks
References
Chapter Five: Overcoming the limitations of cytokines to improve cancer therapy
Abstract
1: Introduction
2: Strategies to modulate the activity
3: Strategies to increase the half-life
4: Strategies to target the tumor microenvironment
5: In vivo production of cytokines
6: Conclusions
Acknowledgments
References
Chapter Six: Emerging applications of nanobodies in cancer therapy
Abstract
1: Introduction
2: Nanobodies: Small antigen-binding proteins with a big impact on conventional cancer therapies
3: Nanobodies: Emerging applications in cancer immunotherapy
4: Conclusion
References

Fernando Aranda Vega

Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.

Affiliations and expertise

Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

Pedro Berraondo

Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.

Affiliations and expertise

CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA